Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Aptevo Participating in the BIO International Convention
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA. The conference is known for being the largest biotechnology industry conference of the year and is expected to attract more than 18,000 attendees from around the world.
